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In this review reasons for diﬃculty with assessment of
treatment response are discussed and general principles
for reducing these problems are advanced. Discussion
focuses on: (1) adoption of common examination pro-
tocols; (2) use of structured reporting of examinations;
and (3) the value of multidisciplinary meetings for
resolution of uncertainty.
Assessment of treatment response involves compari-
son with a previous examination. Thus reproducibility
between serial examinations is vital. Reproducibility is
most likely when the same imaging test is used for serial
examinations and is performed in a similar manner. In
the context of clinical trials and research studies
operator-independent tests such as computed tomogra-
phy (CT) are preferred to ultrasound and increasingly
CT is used in routine clinical practice. Even using CT
there is considerable scope for variation in performance:
enhanced vs. unenhanced; diﬀering contrast techniques;
spiral vs. non-spiral. Key to minimizing variation is the
adoption of common protocols.
The need for reproducibility is emphasized when
patients change institutions, e.g. when referred from a
cancer unit to a cancer centre, or vice versa in shared
care. The evidence from a recent audit of standards of
cross-sectional imaging conducted within the North
West of England[1] was that performance in body CT
was of high quality and that central review of imaging
resulted in a change in treatment for only 4% of
patients[1]. However, the hard copy transferred was
incomplete in one in three cases and the calibration rule
was absent in one in 10. The first deficiency reflects
poorly upon file-keeping. Proponents of PACS and
image transfer will argue that such obstacles can be
surmounted but thus far image transfer at inter-
hospital level has been tested widely only in the con-
text of emergency neuroradiology. Inclusion of a
calibration rule is a basic requirement and this should be
standardized easily.
Modern cancer care must include shared imaging
protocols and shared copy of these examinations. This
works best in an environment of discussion, education
and research. Network groups are developing for indi-
vidual cancers and clinical specialties and the North
West of England has a well-developed centre-led forum
for unit–centre discussion of imaging protocols. The
recent capital replacement programme for CT makes it
more likely that most cancer units can achieve rather
than simply aspire to cancer centre protocols and stan-
dards. The Royal College of Radiologists (RCR) guide-
lines for the use of CT imaging[2] are now almost a
decade old but still provide valuable information and
define a minimum standard for CT examinations which
should now be universally achievable. The document
also includes a few suggestions as to how the findings of
CT examinations should be reported.
A common diﬃculty in routine practice is non-
availability of the previous (comparator) study, whether
performed in-house or at St Elsewhere’s. However, a
report of that examination which clearly records
information on its technique and findings will allow a
reproducible study to be performed and a focused
comparison with recorded marker lesions. A structured
report for such studies improves agreement and under-
standing between radiologists. It also provides clarity
and consistency for clinical colleagues.
Reporting styles vary but use of a framework and
inclusion of a certain key features within the report is
suggested. It is helpful to comment on the clinical
context of and indication for the examination and to
record the diagnosis and reported clinical stage, e.g.
newly diagnosed cancer of cervix, clinically T1b. A
record of this in the imaging history can be valuable
when follow-up requests omit such detail. Further, this
detail indicates the context in which the radiologist
formed his or her assessment. A brief note of the
technique, to ensure consistency in subsequent examin-
ations, should also note any complications or patient
preferences regarding oral or intravenous contrast.
Cancer patients are frequent and discriminating con-
sumers! Description of the key findings should be in
suﬃcient detail for identification of important (marker)
lesions by colleagues by indicating the anatomic site
(lobe or segment), bidimensional measurements and the
table position/slice number at which this assessment was
made. Only a third of examinations in the North West
audit included such data[1]. When comparison is made
with previous studies this should indicate with which
study and its date. Finally, wherever possible a conclu-
sion or impression should, for initial staging or relapse
assessment studies, record tumour stage and bulk using
either the TNM system or the predominantly used
clinical staging scheme and where possible a judgement
regarding treatment options (e.g. suitability for radical
local therapy). For treatment response examinations the
impression should categorize this as partial or complete
response, stable or progressive disease.
Finally, how are uncertainties and problems resolved?
Second review of imaging is widely practised in cancer
care and expert review proves valuable for a significant
minority of patients. Most work has looked at initial
staging examinations rather than in treatment response
assessment. The higher proportion of changed diagnoses
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and management plans after expert review in North
American studies[3–5] than in UK series[1] likely reflects
greater variation in practice standards in the USA.
Review work should ideally occur within the context of
a multidisciplinary team (MDT) meeting. Such work is
time-consuming and requires the attendance of key
radiologists, pathologists, surgeons, physicians and
paramedical staﬀ, as well as the support of administra-
tors and clerical staﬀ. Notes, films and slides must all be
available and in this forum clinical and pathological
information is often brought to light which resolves
problems, downgrades the clinical impact of radiological
uncertainty or else discussion helps to form management
or investigation plans to respond to this. There is little
reported research on the value of such meetings but such
as it is the data are clear. Clinicians place high value on
time spent within such meetings and they are time-
eﬀective for radiologists[6,7].
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The imaging of malignant disease involves tumour
diagnosis, staging, measurement of response and identi-
fication of complications. Increasingly, oncologic radi-
ologists are expected to provide objective assessment of
change in masses, on serial studies, in order to validate
response or resistance to new chemotherapeutic agents.
In some cancer centres follow-up examinations make up
over 75% of computed tomography (CT) activity.
Objective assessment on CT depends on a somewhat
simplistic assumption that those masses that increase in
size define disease progression, whereas reduction in
tumour size indicates a favourable therapeutic impact.
The 1979 WHO Handbook and the 1981 paper by Miller
et al.[1] identified criteria for bi-dimensional measure-
ments of tumour masses and established the classifica-
tion of Complete Response (CR), Partial Response
(PR), Stable Disease (SD) and Progressive Disease
(PD). It has became apparent, however, during the
application of these criteria that assessments based on
bi-dimensional measurements of one or two marker
lesions could result in misleading conclusions, particu-
larly in respect of progressive disease where increasing
size of a single lesion might be at variance with favour-
able change elsewhere. This could lead to an incorrect
conclusion that therapy was ineﬀective. It has also
become clear that methods for evaluating change in the
size of measurable lesions have not always been univer-
sally applied and diﬀerent observers and even centres
could employ diﬀerent regimes. Husband, Gwyther and
Rankin highlighted these features in 1999[2] when they
described the problems of bi-dimensional measurements
of 3-dimensional masses, as well as the diﬃculties posed
by tumour necrosis and calcification.
In June 1999 a revised version of WHO criteria under
the heading ‘Response Evaluation Criteria in Solid
Tumours (RECIST criteria)’[3] was published, based on
the assessment of up to 10 target lesions, the sum of
whose longest diameters define the baseline measure-
ment. The stimulus for this finite objective measurement
emanates from the licensing authorities, whose require-
ments define phase II drug assessment protocols for the
pharmaceutical industry. RECIST criteria require the
identification up to 10 solid, well-marginated nodules
and their repeated identification and assessment of
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